Display Settings:

Format

Send to:

Choose Destination
    In Vivo. 2008 Jul-Aug;22(4):529-36.

    Review. EGFR mutations in non-small cell lung cancer--clinical implications.

    Source

    Oncology Unit, Third Department of Medicine, Athens School of Medicine, Sotiria General Hospital, Athens, Greece.

    Erratum in

    • In Vivo. 2008 Nov-Dec;22(6):886. Anagnostou, Elsa [corrected to Anagnostou, Valsamo].

    Abstract

    The epidermal growth factor receptor (EGFR) family members seem to play a critical role in lung tumourigenesis and are overexpressed in 40-80% of non-small cell lung carcinoma (NSCLC) tumours. EGFR activation results in a series of downstream signaling events that mediate cancer cell growth, proliferation, motility, adhesion, invasion, apoptosis inhibition and metastasis as well as resistance to chemotherapy. Therefore, EGFR inhibitors seem to be an effective therapy for some patients with previously treated NSCLC. A thorough investigation of EGFR, its major signaling pathways, its identification and biology in NSCLC and the responsiveness to gefitinib, erlotinib and cetuximab in connection to EGFR mutations as well as the possible mechanisms of resistance to tyrosine kinase inhibitors is the scope of this review.

    PMID:
    18712184
    [PubMed - indexed for MEDLINE]
    Free full text

      Supplemental Content

      Icon for HighWire Press

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk